Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Sams, Anette G.
Hentzer, Morten
Mikkelsen, Gitte K.
Larsen, Krestian
Bundgaard, Christoffer
Plath, Niels
Christoffersen, Claus T.
and
Bang-Andersen, Benny
2010.
Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M1 Receptor Agonist with Unprecedented Selectivity and Procognitive Potential.
Journal of Medicinal Chemistry,
Vol. 53,
Issue. 17,
p.
6386.
Zink, Mathias
Englisch, Susanne
and
Meyer-Lindenberg, Andreas
2010.
Polypharmacy in schizophrenia.
Current Opinion in Psychiatry,
Vol. 23,
Issue. 2,
p.
103.
Barak, Segev
and
Weiner, Ina
2010.
Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.
Psychopharmacology,
Vol. 209,
Issue. 2,
p.
175.
Dome, Peter
Lazary, Judit
Kalapos, Miklos Peter
and
Rihmer, Zoltan
2010.
Smoking, nicotine and neuropsychiatric disorders.
Neuroscience & Biobehavioral Reviews,
Vol. 34,
Issue. 3,
p.
295.
Yamamoto, Shigeyuki
Ohba, Hiroyuki
Nishiyama, Shingo
Takahashi, Kazuhiro
and
Tsukada, Hideo
2011.
Validation of reference tissue model of PET ligand [11C](+)3‐MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey.
Synapse,
Vol. 65,
Issue. 6,
p.
548.
Bartko, Susan J.
Romberg, Carola
White, Benjamin
Wess, Jürgen
Bussey, Timothy J.
and
Saksida, Lisa M.
2011.
Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.
Neuropharmacology,
Vol. 61,
Issue. 8,
p.
1366.
Yamamoto, Shigeyuki
Nishiyama, Shingo
Kawamata, Masahiro
Ohba, Hiroyuki
Wakuda, Tomoyasu
Takei, Nori
Tsukada, Hideo
and
Domino, Edward F
2011.
Muscarinic Receptor Occupancy and Cognitive Impairment: A PET Study with [11C](+)3-MPB and Scopolamine in Conscious Monkeys.
Neuropsychopharmacology,
Vol. 36,
Issue. 7,
p.
1455.
Altınyazar, Vesile
and
Yüksel, Nevzat
2011.
Şizofrenide Kombinasyon Tedavileri.
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology,
Vol. 21,
Issue. 4,
p.
368.
Yamamoto, Shigeyuki
Maruyama, Shuji
Ito, Yoshihiko
Kawamata, Masahiro
Nishiyama, Shingo
Ohba, Hiroyuki
Yamada, Shizuo
and
Tsukada, Hideo
2011.
Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: A monkey PET study with [11C](+)3-MPB.
NeuroImage,
Vol. 58,
Issue. 1,
p.
1.
Kuduk, Scott D
and
Beshore, Douglas C
2012.
Novel M1allosteric ligands: a patent review.
Expert Opinion on Therapeutic Patents,
Vol. 22,
Issue. 12,
p.
1385.
Sams, Anette Graven
Larsen, Krestian
Mikkelsen, Gitte Kobberøe
Hentzer, Morten
Christoffersen, Claus Tornby
Jensen, Klaus Gjervig
Frederiksen, Kristen
and
Bang-Andersen, Benny
2012.
Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential.
Bioorganic & Medicinal Chemistry Letters,
Vol. 22,
Issue. 15,
p.
5134.
Pohanka, Miroslav
2012.
Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology.
International Journal of Molecular Sciences,
Vol. 13,
Issue. 2,
p.
2219.
Decker, Michael
and
Holzgrabe, Ulrike
2012.
M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease.
MedChemComm,
Vol. 3,
Issue. 7,
p.
752.
Lameh, Jelveh
McFarland, Krista
Ohlsson, Jorgen
Ek, Fredrik
Piu, Fabrice
Burstein, Ethan S.
Tabatabaei, Ali
Olsson, Roger
Bradley, Stefania Risso
and
Bonhaus, Douglas W.
2012.
Discovery of potential antipsychotic agents possessing pro-cognitive properties.
Naunyn-Schmiedeberg's Archives of Pharmacology,
Vol. 385,
Issue. 3,
p.
313.
D’Souza, Manoranjan S.
and
Markou, Athina
2012.
Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.
Neuropharmacology,
Vol. 62,
Issue. 3,
p.
1564.
Yanagi, Masaya
Southcott, Sarah
Lister, Jacob
and
Tamminga, Carol A.
2012.
Animal Models of Molecular Pathology.
Vol. 105,
Issue. ,
p.
411.
Bolbecker, Amanda R.
and
Shekhar, Anantha
2012.
Muscarinic Receptors.
Vol. 208,
Issue. ,
p.
167.
Wan, Hong I
Soares, Holly
and
Waring, Jeffrey F
2012.
Use of Cerebrospinal Fluid Biomarkers in Clinical Trials for Schizophrenia and Depression.
Biomarkers in Medicine,
Vol. 6,
Issue. 1,
p.
119.
Felder, Christian C.
McKinzie, David L.
Thompson, Richard C.
and
Liu, Bin
2012.
Targets and Emerging Therapies for Schizophrenia.
p.
355.
Bussey, T.J.
Holmes, A.
Lyon, L.
Mar, A.C.
McAllister, K.A.L.
Nithianantharajah, J.
Oomen, C.A.
and
Saksida, L.M.
2012.
New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats.
Neuropharmacology,
Vol. 62,
Issue. 3,
p.
1191.